scispace - formally typeset
P

Paulus Kirchhof

Researcher at University of Birmingham

Publications -  659
Citations -  119822

Paulus Kirchhof is an academic researcher from University of Birmingham. The author has contributed to research in topics: Atrial fibrillation & Medicine. The author has an hindex of 100, co-authored 558 publications receiving 106459 citations. Previous affiliations of Paulus Kirchhof include United States Department of Veterans Affairs & Georgetown University Medical Center.

Papers
More filters
Journal ArticleDOI

The EAST study: redefining the role of rhythmcontrol therapy in atrial fibrillation: EAST, the Early treatment of Atrial fibrillation for Stroke prevention Trial.

TL;DR: Atrial fibrillation is not only a common condition and increasingly so in ageing populations, it is also a common cause of stroke, cardiovascular death, and cardiovascular hospitalizations, illustrating the unmet needs in the current evidence-based management of AF.
Journal ArticleDOI

Inhibitor-2 prevents protein phosphatase 1-induced cardiac hypertrophy and mortality

TL;DR: PP1 mice were crossed with mice that overexpress a functional COOH-terminally truncated form of PP1 inhibitor-2 (I-2(140)), indicating that I-2 overexpression prevents the detrimental effects of PP 1 overexpressive in the heart and further underscore the fundamental role ofPP1 in cardiac function.
Journal ArticleDOI

Fetoscopic transesophageal electrocardiography and stimulation in fetal sheep: a minimally invasive approach aimed at diagnosis and termination of therapy-refractory supraventricular tachycardias in human fetuses.

TL;DR: Fetoscopic fetal transesophageal electrocardiography and stimulation are feasible in fetal sheep and might have the potential to improve diagnosis and management of therapy-refractory supraventricular tachycardias in human fetuses.
Journal ArticleDOI

Influence of age and shock severity on short-term survival in patients with cardiogenic shock

TL;DR: In this article, the associations between age and shock severity on mortality among patients with Cardiogenic shock were determined using Cox proportional-hazards analysis, with a clear gradient towards lower 30-day survival as a function of increasing age and SCAI shock stages.